Cost-utility of tiotropium in patients with severe asthma
Abstract Summary Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country. Background A significant proportion of asthma patients remain uncontrolled despite inhaled c...
Main Authors: | Jefferson Antonio Buendía, Diana Guerrero Patiño |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Cost Effectiveness and Resource Allocation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12962-023-00508-x |
Similar Items
-
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
by: Zafar Zafari, et al.
Published: (2018-01-01) -
Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma
by: Jefferson Antonio Buendía, et al.
Published: (2021-12-01) -
Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients
by: Zielen S, et al.
Published: (2021-01-01) -
Role of Tiotropium as Step Up Therapy for Asthma
by: Muhammad Usman Ullah
Published: (2013-12-01) -
The evolving role of tiotropium in asthma
by: McIvor ER, et al.
Published: (2017-08-01)